Searched for
UTI
Largecaps over midcaps, banks over PSUs: V Srivatsa reveals where smart money is headingIndia's market outlook is positive, driven by cooling geopolitical tensions and falling crude oil prices, according to UTI AMC's V Srivatsa...24 Jun, 2026, 05.13 PM IST- Societe General, Prudential, others buy 3 per cent stake in Anthem Biosciences for Rs 1,275 crGlobal investors including Societe Generale and Prudential Hong Kong, alongside Indian mutual funds and insurance companies, have bought a ...19 Jun, 2026, 01.15 PM IST
- Best flexi cap mutual funds to invest in June 2026Flexi cap mutual funds provide a flexible investment avenue for investors navigating market volatility. Fund managers can strategically all...10 Jun, 2026, 09.25 AM IST
- Edelweiss Alternatives’ Subahoo Chordia quits, likely to launch own fundSubahoo Chordia, a key figure at Edelweiss Alternatives, has departed to launch his own infrastructure fund. He was instrumental in buildin...08 Jun, 2026, 05.25 PM IST
- Gold and silver ETFs slip up to 8% amid Israel attack and crude oil spike. What should investors do?Gold and silver ETFs declined sharply on Monday as precious metal prices corrected on the MCX amid rising crude oil prices, inflation conce...08 Jun, 2026, 02.47 PM IST
- Every mutual fund offers positive XIRR on SIP investments in 5 years. Did you exit too soon?Equity mutual funds delivered positive returns on Systematic Investment Plans over the past five years. Many funds provided double-digit XI...03 Jun, 2026, 01.16 PM IST
- Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What’s behind the selloff?Wockhardt shares dropped after a recent surge, as investors took profits. This followed the US FDA approval of ZAYNICH, an antibiotic for u...02 Jun, 2026, 11.10 AM IST
- Crude oil shock clouds near-term outlook, but FY27 earnings growth still intact: Karthikraj LakshmananUTI AMC's Karthikraj Lakshmanan sees cautiously optimistic Indian market outlook with intact FY27 earnings trajectory, despite near-term cr...01 Jun, 2026, 01.43 PM IST
- Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check detailsWockhardt's shares surged 19% after the U.S. FDA approved ZAYNICH, a novel intravenous antibiotic for complicated urinary tract infections....01 Jun, 2026, 10.11 AM IST
- FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics marketWockhardt's new antibiotic, Zaynich, has received US FDA approval. This drug uses a novel mechanism to fight drug-resistant bacteria. It ta...01 Jun, 2026, 07.44 AM IST
- 20 months of bearish markets: One additional letter that tells you which 'cheap' stocks are actually cheapMost investors live by one ratio. That ratio that tells them all they want to know – or should one say all they want to hear? They open a s...31 May, 2026, 07.56 AM IST
- Wockhardt secures US FDA approval for antibiotic ZaynichWockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. Thi...30 May, 2026, 11.17 PM IST
- Wockhardt shares jump 8%, extend rally after CDSCO nod for Zaynich antibioticWockhardt shares surged after the company received CDSCO approval for its breakthrough antibiotic Zaynich in India. Strong Phase 3 trial re...29 May, 2026, 11.05 AM IST
- Wockhardt gets CDSCO nod for Zaynich antibioticWockhardt Ltd has secured approval from the CDSCO for its new antibiotic, Zaynich. This drug is developed in India and will be used to trea...28 May, 2026, 11.52 AM IST
- MF Tracker: Parag Parikh Flexi Cap Fund turns Rs 10,000 SIP to over Rs 51 lakh in 13 years. Too late to invest?Parag Parikh Flexi Cap Fund marks 13 years with impressive growth. A Rs 10,000 SIP since inception turned into Rs 51 lakh. The fund priorit...28 May, 2026, 10.08 AM IST
- Mutual funds cut technology sector exposure to 8-year low in April. Is AI disruption reshaping sentiment?Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...18 May, 2026, 10.31 AM IST
- Jhunjhunwala-backed Bagmane Prime Office REIT lists at 3.5% premium over IPO priceBagmane Prime Office REIT debuted on the NSE at Rs 103.50, a 3.5% premium to its IPO price, following a highly subscribed Rs 3,405 crore of...14 May, 2026, 10.11 AM IST
Load More
